期刊
NATURE REVIEWS RHEUMATOLOGY
卷 13, 期 10, 页码 578-592出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrrheum.2017.142
关键词
-
类别
资金
- AbbVie
- Lilly
- Merck
- MSD
- Novartis
- Pfizer
- Roche
- Sandoz
- UCB
- Janssen
- Galapagos
- Horizon Pharma
- Mundipharma
- Bristol Meyer Squibb
- Genentech
- GSK
- Hoffman-LaRoche
- Napp
- Celgene
- Fight for Sight [24PMR13] Funding Source: researchfish
The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据